Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Regulating oestrogen in men may lead to treatment for prostate cancer and benign prostate hyperplasia

06.11.2006
A special type of oestrogen-regulating drug may reverse the progression of prostate cancer and prostate swelling (benign prostate hyperplasia, or BHP), according to a group from Monash University, Melbourne presenting its results at the Society for Endocrinology conference in London.

Oestrogens are normally thought of as a female hormone, but recently scientists have found that oestrogens have vital roles to play in men’s health; without estrogens at all men are tall and overweight and develop diabetes. Now scientists are beginning to realise that oestrogen also has a major role to play in the development of the prostate gland and may contribute to common male problems, prostate cancer and BHP.

Prostate cancer is the most common cancer in British men, with more than 30,000 new cases diagnosed every year. 43% of British men over the age of 65 suffer from BHP.

There are two types of receptors for the hormone oestrogen, oestrogen-receptor-alpha and oestrogen receptor-beta. A group of scientists led by Professor Gail Risbridger (Monash University, Melbourne) have tested compounds that selectively activate one but not the other receptor. Thus, they can turn on one receptor eg oestrogen receptor alpha without affecting oestrogen receptor beta and vice versa.

Working in animals, they found that regulating the oestrogen receptor beta was beneficial and stopped the development of prostate hyperplasia. Whereas the bad effects of estrogens are due to activation of the oestrogen receptor alpha and are linked to malignancy.

Presenting her results at the conference in London, Professor Risbridger said

“We still have to try the drugs in humans, but so far these are very promising results. This work holds out the possibility that we may be able to help patients with benign disease as well as men with prostate cancer, by using these designer drugs.

Ideally, we would want to promote the good effects of oestrogen receptor beta and block the bad effects of oestrogen receptor alpha.

It's interesting work, and we are pleased that preclinical testing may translate into real benefits for patients”.

The work is being presented at the Society for Endocrinology conference, but it has also just been accepted for publication in the journal Endocrinology; for the abstract of the Endocrinology article, see:

http://endo.endojournals.org/cgi/content/abstract/en.2006-0906v1

Jo Thurston | alfa
Further information:
http://www.endocrinology.org
http://endo.endojournals.org/cgi/content/abstract/en.2006-0906v1

More articles from Health and Medicine:

nachricht Spanish scientists create a 3-D bioprinter to print human skin
24.01.2017 | Carlos III University of Madrid

nachricht Tracking movement of immune cells identifies key first steps in inflammatory arthritis
23.01.2017 | Massachusetts General Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists spin artificial silk from whey protein

X-ray study throws light on key process for production

A Swedish-German team of researchers has cleared up a key process for the artificial production of silk. With the help of the intense X-rays from DESY's...

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Breaking the optical bandwidth record of stable pulsed lasers

24.01.2017 | Physics and Astronomy

Choreographing the microRNA-target dance

24.01.2017 | Life Sciences

Spanish scientists create a 3-D bioprinter to print human skin

24.01.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>